ITCC 054

About this trial

This is a Phase 1-2, multicenter, international, single-arm, open-label study designed to identify a recommended dose of bosutinib administered orally once daily in pediatric patients with CML who have received at least one prior TKI therapy, and to preliminary estimate the efficacy, safety, and tolerability of the selected bosutinib dose and evaluate the PK in this patient population.

Patient Profile

CML resistant/intolerant to at least one prior Tyrosine Kinase Inhibitor treatment.

Where’s this trial being run?

Crumlin Children’s Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information


Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: ITCC 054
Number: 18-24
Full Title:

A phase I/II study of Bosutinib in pediatric patients with Chronic Myeloid Leukemia who are resistant or intolerant to at least one prior Tyrosine Kinase Inhibitor therapy, ITCC-054.

Principal Investigator: Dr Owen Smith
Type: Collaborative

Erasmus Medical Centre

Recruitment Started: Global: Not Available
Ireland: Not Available
Global Recruitment Target: Not Available
Ireland Recruitment Target: Not Available